Secondary Logo

Journal Logo

Most Popular Articles

Impact of COVID-19 of oncology pharmacy services: Results of 8-months survey

Bienert, Agnieszka; Meier, Klaus; Kokisheva, Antonina; More

European Journal of Oncology Pharmacy. 5(1):e00036, January-March 2022.

Needs of chemotherapy regimen checks procedure: from the survey on chemotherapy regimen checks performed by pharmacists in hospitals other than designated cancer hospitals in Japan

Ohta, Takahiro; Suzuki, Shinya; Shinohara, Akira; More

European Journal of Oncology Pharmacy. 4(4):e00035, October-December 2021.

Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique – SFPO) guidelines

Petit-Jean, Emilie; Correard, Florian; Maillan, Gaelle; More

European Journal of Oncology Pharmacy. 2(2):e11, April-June 2019.

Drug cost savings resulting from the outpatient pharmacy services collaborating with oncologists at outpatient clinics

Kamata, Hayato; Suzuki, Shinya; Demachi, Ken; More

European Journal of Oncology Pharmacy. 3(1):e22, January-March 2020.

Reduction of patient waiting time by the preparation and administration of trastuzumab and pertuzumab in a single infusion bag: a 1-year review, retrospective, single institution experience in a French cancer center

Deppenweiler, Marine; Teytaud, Manon; Stein, Philippe; More

European Journal of Oncology Pharmacy. 4(2):e029, April-June 2021.

Impact of outpatient pharmacy services collaborating with oncologists at an outpatient clinic for outpatient chemotherapy prescription orders

Demachi, Ken; Suzuki, Shinya; Kamata, Hayato; More

European Journal of Oncology Pharmacy. 2(1):e10, January-March 2019.

Synadenium umbellatum and the Ehrlich's solid tumor treatment: Assessment of inflammatory regulators (transforming growth factor protein-β1 and tumor necrosis factor-α) gene expression, hepatotoxicity and myelotoxicity

da Silva, Emerson B.; Chagas, Camila S.; Fonseca, Alexandre L. A.; More

European Journal of Oncology Pharmacy. 2(1):e9, January-March 2019.

Grade 3 infusion-related reaction because of cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5 mg, dexamethasone 13.2 mg, and aprepitant 125 mg premedication

Horinouchi, Ai; Suzuki, Shinya; Enokida, Tomohiro; More

European Journal of Oncology Pharmacy. 3(1):e21, January-March 2020.

Show: